1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Malaseb shampoo for dogs and cats (AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LV, NL, PL, PT, RO, SI, UK (NI))
Malaseb Vet. (DK, SK)

Malaseb vet. 20 mg/ml + 20 mg/ml shampoo (FI, IS, SE)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:

Chlorhexidine digluconate 20 mg (equivalent to chlorhexidine 11.26 mg) Miconazole nitrate 20 mg (equivalent to miconazole 17.37 mg)

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Methylchloroisothiazolinone	0.0075 mg
Methylisothiazolinone	0.0025 mg
Sodium Benzoate	1.25 mg
Macrogol lauryl ether	
Cocamidopropyl Betaine	
Disodium cocoamphodiacetate	
Cetrimonium chloride	
PEG-120 methyl glucose dioleate	
Citric acid monohydrate	
Hydrochloric acid	
Water, purified	

A clear to slightly unclear, light yellow to light brown liquid.

3. CLINICAL INFORMATION

3.1 Target species

Dogs and cats.

3.2 Indications for use for each target species

<u>Dogs</u>: For the treatment and control of seborrhoeic dermatitis associated with *Malassezia* pachydermatis and *Staphylococcus intermedius*.

<u>Cats</u>: As an aid in the treatment of ringworm due to *Microsporum canis* in conjunction with griseofulvin.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

3.4 Special warnings

Dogs and cats:

In order to prevent reoccurrence of the infection, appropriate control methods should be employed in the animal's environment (e.g. cleaning and disinfection of kennels, beds).

Cats:

The veterinary medicinal product should only be used in conjunction with griseofulvin when treating for ringworm.

Shampooing cats may initially increase the recovery of *M. canis* by brush culture techniques. Both field and experimental studies have shown that environmental contamination with *M. canis* can be eliminated or reduced by the use of the veterinary medicinal product twice weekly. In these studies, griseofulvin was administered continuously throughout the treatment period and both clinical improvement was enhanced and environmental contamination reduced compared to the use of griseofulvin alone.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies.

For external use only.

In case of accidental contact with eyes, rinse with plenty of water.

Do not allow the animal to lick itself during shampooing and rinsing, or before it is dried. Take care to avoid the animal inhaling the veterinary medicinal product or getting it into the nose or mouth during shampooing.

Puppies and kittens should not come into contact with nursing females after treatment until the coat has dried.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to chlorhexidine, miconazole or any of the excipients should avoid contact with the veterinary medicinal product.

This veterinary medicinal product can cause eye irritation. Avoid contact with the eyes. In case of accidental contact with eyes, rinse with plenty of water. If irritation persists consult your doctor.

Avoid excessive handling and stroking of treated animals immediately following treatment.

Ringworm in the cat is infectious to humans and so it is advisable to wear gloves and have arms covered during clipping and shampooing of infected cats.

When shampooing a cat, in order to avoid prolonged contact with the shampoo, wash and dry hands gently. Do not scrub.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs, cats:

Very rare	Application site erythema ^a , Application site pruritus ^a
(<1 animal / 10,000 animals treated, including isolated reports):	Skin reaction (itching, reddening of the skin)

^a Exceptionally in dogs with atopy or cats with allergic skin disease.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The veterinary medicinal product in conjunction with griseofulvin should not be used in pregnant cats as griseofulvin is contra-indicated in pregnancy.

Please see section 3.5.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

3.9 Administration routes and dosage

Cutaneous use.

<u>Dogs</u>: As a general rule, shampoo twice weekly until the symptoms subside and weekly thereafter or as necessary to keep the condition under control.

<u>Cats</u>: Shampoo twice weekly for a minimum period until coat brushings are negative for the culture of *M. canis*. The maximum length of the treatment period should not exceed 16 weeks. Depending on the length and type of the haircoat it should be considered whether it is necessary to clip the haircoat of the cat prior to treatment.

Wet the animal thoroughly with clean water and apply the veterinary medicinal product to the animal at several points and massage into the coat. Use a sufficient amount of the shampoo to raise a lather on the coat and skin. Ensure that the shampoo is applied around the lips, under the tail and between the toes. Allow the animal to stand for 10 minutes, then rinse off with clean water and leave to dry naturally in a warm, draught-free environment.

The 250 ml bottle, for example, provides approximately 8-16 treatments for a 15 kg dog, or 5-10 treatments for a 25 kg dog or 25 cat treatments, depending on coat thickness.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

OD01AC52

4.2 Pharmacodynamics

<u>Chlorhexidine digluconate</u>:

Chlorhexidine digluconate is a Bisbiguanide antimicrobial agent against Gram-positive and Gram-negative bacteria. It is both bactericidal and bacteriostatic depending on the concentration used. Growth inhibition is achieved by a direct effect on ATP-ase so interfering with the energy transport mechanisms. The bactericidal effect of chlorhexidine results from coagulation of the bacterial cell contents

Chlorhexidine digluconate is incorporated in the veterinary medicinal product for its activity against *Staphylococcus intermedius*. Typical MIC values found in clinical *Staphylococcus intermedius* isolates are 2.0 mg/l (2005). *Staphylococcus intermedius* resistance to chlorhexidine has not been reported.

Miconazole nitrate:

Miconazole nitrate is an imidazole antifungal agent with activity against yeasts such as *Malassezia* pachydermatis.

It is both fungicidal and fungistatic depending on the concentration used. Miconazole inhibits ergosterol incorporation into cell membranes so increasing concentrations of cytotoxic hydrogen peroxide within the fungal cell wall.

Miconazole nitrate has been incorporated in the veterinary medicinal product for its activity against *Malassezia pachydermatis*. Typical MIC values found in clinical *Malassezia pachydermatis* isolates are 0.5-4.0 mg/l (2003/5). *Malassezia pachydermatis* resistance to miconazole has not been reported.

Chlorhexidine and miconazole in combination:

In vitro studies have demonstrated synergistic activity against *Microsporum canis* between chlorhexidine and miconazole.

4.3 Pharmacokinetics

Chlorhexidine digluconate:

High concentrations of chlorhexidine digluconate are achieved in the hair coat and on the skin for the 10 minute period following shampooing. These concentrations are well in excess of the MICs for *Staphylococcus intermedius*. Chlorhexidine digluconate is poorly absorbed from the gastrointestinal tract on ingestion. There is little or no percutaneous absorption. In humans, it has been shown that 26% remains on the skin at 29 hours after application.

Miconazole nitrate:

High concentrations of miconazole nitrate are achieved in the hair coat and on the skin for the 10 minute period following shampooing. These concentrations are well in excess of the MICs for *Malassezia pachydermatis*.

Miconazole nitrate is poorly absorbed from the skin and gastrointestinal tract.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 3 months.

5.3 Special precautions for storage

Do not store above 30 °C. Do not refrigerate or freeze.

5.4 Nature and composition of immediate packaging

The container is a 250 ml polyethylene bottle with a polypropylene screw cap.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

- 7. MARKETING AUTHORISATION NUMBER(S)
- 8. DATE OF FIRST AUTHORISATION
- 9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the <u>Union Product Database</u> (<u>https://medicines.health.europa.eu/veterinary</u>).

ANNEX III LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE		
LABEL		
1 NAME OF THE VETEDINADY MEDICINAL DOODLOT		
1. NAME OF THE VETERINARY MEDICINAL PRODUCT		
Malaseb shampoo		
2. STATEMENT OF ACTIVE SUBSTANCES		
Each ml contains:		
Chlorhexidine digluconate 20 mg (equivalent to chlorhexidine 11.26 mg)		
Miconazole nitrate 20 mg (equivalent to miconazole 17.37 mg)		
3. PACKAGE SIZE		
250 ml		
230 III		
4. TARGET SPECIES		
4. TARGET SPECIES		
Dogs and cats.		
5. INDICATIONS		
6. ROUTES OF ADMINISTRATION		
Cutaneous use. Read the package leaflet before use.		
Read the package learner before use.		
T WITHIN AWAI DEDIADS		
7. WITHDRAWAL PERIODS		
8. EXPIRY DATE		
Exp. {mm/yyyy}		
Once opened use within 3 months, use by		
9. SPECIAL STORAGE PRECAUTIONS		
Do not stone shows 20.9C		
Do not store above 30 °C. Do not refrigerate or freeze.		

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

10.

Read the package leaflet before use.

Lot {number}

11. THE	WORDS "FOR ANIMAL TREATMENT ONLY"
For animal ti	reatment only.
12. THE	WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"
TZ . C.	
Keep out of	the sight and reach of children.
13. NAM	E OF THE MARKETING AUTHORISATION HOLDER
14. MAR	KETING AUTHORISATION NUMBERS
14. MAK	RETING AUTHORISATION NUMBERS
15. BATC	CH NUMBER

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Malaseb shampoo for dogs and cats

2. Composition

Each ml contains:

Active substances:

Chlorhexidine digluconate 20 mg (equivalent to chlorhexidine 11.26 mg) Miconazole nitrate 20 mg (equivalent to miconazole 17.37 mg)

Excipients:

Methylchloroisothiazolinone 0.0075 mg Methylisothiazolinone 0.0025 mg Sodium benzoate 1.25 mg

A clear to slightly unclear, light yellow to light brown liquid.

3. Target species

Dogs and cats.

4. Indications for use

For the treatment and control of seborrhoeic dermatitis associated with *Malassezia pachydermatis* and *Staphylococcus intermedius* in dogs.

As an aid in the treatment of ringworm due to *Microsporum canis* in the cat in conjunction with griseofulvin.

5. Contraindications

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

6. Special warnings

Special warnings:

Cats: The veterinary medicinal product should only be used in conjunction with griseofulvin when treating for ringworm. Shampooing cats may initially increase the recovery of *M. canis* by brush culture techniques.

Both field and experimental studies have shown that environmental contamination with *M. canis* can be eliminated or reduced by the use of the veterinary medicinal product twice weekly. In these studies, griseofulvin was administered continuously throughout the treatment period and both clinical improvement was enhanced and environmental contamination reduced compared to the use of griseofulvin alone.

Dogs and cats: In order to prevent reoccurrence of the infection, appropriate control methods should be employed in the animal's environment (e.g. cleaning and disinfection of kennels, beds etc.)

Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies.

For external use only.

In case of accidental contact with eyes, rinse with plenty of water.

Do not allow the animal to lick itself during shampooing and rinsing, or before it is dried. Take care to avoid the animal inhaling the veterinary medicinal product or getting it into the nose or mouth during shampooing.

Puppies and kittens should not come into contact with nursing females after treatment until the coat has dried.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to chlorhexidine, miconazole or any of the excipients should avoid contact with the veterinary medicinal product.

This veterinary medicinal product can cause eye irritation. Avoid contact with the eyes. In case of accidental contact with eyes, rinse with plenty of water. If irritation persists, consult your doctor. Avoid excessive handling and stroking of treated animals immediately following treatment.

Ringworm in the cat is infectious to humans, and so it is advisable to wear gloves and have arms covered during clipping and shampooing of infected cats.

When shampooing a cat, in order to avoid prolonged contact with the shampoo, wash and dry hands gently. Do not scrub.

Pregnancy and lactation:

The veterinary medicinal product in conjunction with griseofulvin should not be used in pregnant cats as griseofulvin is contra-indicated in pregnancy.

See also section 'Special precautions for safe use in the target species'.

7. Adverse events

Dogs, cats:

Very rare	Application site erythema ^a , Application site pruritus ^a
(<1 animal / 10,000 animals treated,	Skin reaction (itching, reddening of the skin)
including isolated reports):	

^a Exceptionally in dogs with atopy or cats with allergic skin disease.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Cutaneous use.

<u>Dogs</u>: As a general rule, shampoo twice weekly until the symptoms subside and weekly thereafter or as necessary to keep the condition under control as advised by your veterinary surgeon.

<u>Cats</u>: Shampoo twice weekly for a minimum period until coat brushings are negative for the culture of *M. canis*. The maximum length of the treatment period should not exceed 16 weeks. Depending on the length and the type of the haircoat it should be considered whether it is necessary to clip the haircoat of the cat prior to treatment.

9. Advice on correct administration

Wet the animal thoroughly with clean water. Apply the shampoo to the animal at several points and massage into the coat especially around the lips, under the tail and between the toes. **Make sure that a sufficient amount of the shampoo is used to raise a lather. Allow the animal to stand for 10 minutes, then rinse off with clean water and leave to dry naturally in a warm, draught-free environment.** The 250 ml bottle provides approximately 8-16 treatments for a 15 kg dog or 5-10 treatments for a 25 kg dog or 25 cat treatments, depending on coat thickness.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 30 °C. Do not refrigerate or freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 3 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Pack size: 250 ml

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the <u>Union Product Database</u> (https://medicines.health.europa.eu/veterinary).

16. Contact details

<u>Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:</u>

Manufacturer responsible for batch release:

Genera d.d. Svetonedeljska cesta 2 Kalinovica 10436 Rakov Potok Croatia

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information